- Home
- AIMD vs NERV Comparison
AIMD vs NERV Comparison
Compare AIMD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- NERV
- Stock Information
- Founded
- AIMD 1984
- NERV 2007
- Country
- AIMD United States
- NERV United States
- Employees
- AIMD N/A
- NERV N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- NERV Health Care
- Exchange
- AIMD Nasdaq
- NERV Nasdaq
- Market Cap
- AIMD 11.9M
- NERV 12.0M
- IPO Year
- AIMD N/A
- NERV 2014
- Fundamental
- Price
- AIMD $2.33
- NERV $1.84
- Analyst Decision
- AIMD
- NERV Hold
- Analyst Count
- AIMD 0
- NERV 1
- Target Price
- AIMD N/A
- NERV $5.00
- AVG Volume (30 Days)
- AIMD 134.7K
- NERV 20.6K
- Earning Date
- AIMD 08-15-2025
- NERV 08-12-2025
- Dividend Yield
- AIMD N/A
- NERV N/A
- EPS Growth
- AIMD N/A
- NERV N/A
- EPS
- AIMD N/A
- NERV 0.83
- Revenue
- AIMD $106,207.00
- NERV N/A
- Revenue This Year
- AIMD N/A
- NERV N/A
- Revenue Next Year
- AIMD N/A
- NERV N/A
- P/E Ratio
- AIMD N/A
- NERV $2.29
- Revenue Growth
- AIMD 13.38
- NERV N/A
- 52 Week Low
- AIMD $2.00
- NERV $1.15
- 52 Week High
- AIMD $5.00
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- AIMD 36.64
- NERV 47.09
- Support Level
- AIMD $2.40
- NERV $1.87
- Resistance Level
- AIMD $2.66
- NERV $1.95
- Average True Range (ATR)
- AIMD 0.19
- NERV 0.13
- MACD
- AIMD -0.04
- NERV -0.02
- Stochastic Oscillator
- AIMD 11.77
- NERV 7.77
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.